Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects

• Published in: Clinical pharmacokinetics Vol. 58; no. 9; pp. 1193 - 1203
• Main Authors: Bækdal, Tine A., Borregaard, Jeanett, Hansen, Cilie W., Thomsen, Mette, Anderson, Thomas W.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2019; Springer Nature B.V
• Subjects: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors - pharmacokinetics; Anticoagulants; Anticoagulants - pharmacokinetics; Antidiabetics; Caprylates - administration & dosage; Cardiotonic Agents - pharmacokinetics; Case-Control Studies; Cross-Over Studies; Diabetes; Digoxin - pharmacokinetics; Drug dosages; Drug Interactions; Female; Glucagon; Glucagon-Like Peptide 1 - administration & dosage; Glucagon-Like Peptide 1 - adverse effects; Glucagon-Like Peptide 1 - pharmacology; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - pharmacology; Healthy Volunteers; Humans; Hypoglycemic Agents - pharmacokinetics; Internal Medicine; Lisinopril - pharmacokinetics; Male; Medicine; Medicine & Public Health; Metformin - pharmacokinetics; Middle Aged; Original; Original Research Article; Peptides; Permeability; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Warfarin - pharmacokinetics

Background Oral semaglutide is a tablet co-formulation of the human glucagon-like peptide-1 (GLP-1) analog semaglutide with the absorption enhancer sodium N -(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The absorption of coadministered oral drugs may be altered due to enhancement by SNAC, potentia...